Literature DB >> 29339633

Multiple Sclerosis Mortality by Race/Ethnicity, Age, Sex, and Time Period in the United States, 1999-2015.

Lilyana Amezcua1, Erica Rivas1, Sarah Joseph1, Juanjuan Zhang2, Lihua Liu2.   

Abstract

BACKGROUND: Multiple sclerosis (MS) carries high morbidity and shortens life span. While there is recent recognition of other US minority populations such as blacks and Hispanics being affected with MS, examination of MS-specific mortality trends by race/ethnicity has been lacking.
OBJECTIVE: To investigate MS mortality rates and trends in the United States by sex, age, and race/ethnicity.
METHODS: We used the Compressed Mortality data file for 1999-2015 in the Wide-ranging online Data for Epidemiological Research system developed by the Center for Disease Control and Prevention to calculate the age-adjusted (US 2000 standard population) and age-specific MS mortality rate (per 100,000) by race/ethnicity and sex over time. Five mutually exclusive racial/ethnic groups were included in the analysis: non-Hispanic (NH) white, NH black, NH Asian or Pacific Islander (API), NH American Indian or Alaska Native, and Hispanic.
RESULTS: The average annual age-adjusted MS mortality rate was highest among NH whites (0.90 for males and 1.50 for females) immediately followed by NH blacks (0.75 for males and 1.42 for females), and lowest among APIs (0.05 for males and 0.12 for females). Statistically significant, increasing trend in age-adjusted MS mortality was observed during 1999-2015 among NH whites and NH blacks regardless of sex, more substantially in the latter. Age-specific MS mortality patterns showed NH blacks had the highest rate under age 55 and NH whites had the highest rate after that age point. For these 2 groups, MS mortality increased with age in both sexes and peaked at ages 55-64 for NH blacks and 65-74 for NH whites before declining substantially, while for Hispanic and API groups the risk plateaued after age 55.
CONCLUSION: MS-specific mortality trends demonstrate distinctive differences by race/ethnicity and age. The observations that whites and females are more likely to die from MS is in line with the overall understanding that these groups are affected more by MS. However, the findings of blacks dying at an earlier age and having more substantially increasing mortality trends than whites suggest that MS burden weighs unequally by race. Further investigation into these trends may provide additional evidence into risk or protective factors within each group.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Epidemiology; Ethnicity; Mortality; Multiple sclerosis; Race

Mesh:

Year:  2018        PMID: 29339633     DOI: 10.1159/000484213

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  11 in total

1.  Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences.

Authors:  Taylor Olmsted Kim; Amanda B Grimes; Susan E Kirk; Megan M Gilbert; Helen D Reed; Kristen A Staggers; Lauryn A Walker; Abinaya Arulselvan; A Sarah Cohen; Michele P Lambert; Jenny M Despotovic
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

Review 2.  Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.

Authors:  Annette F Okai; Annette M Howard; Mitzi J Williams; Justine D Brink; Chiayi Chen; Tamela L Stuchiner; Elizabeth Baraban; Grace Jeong; Stanley L Cohan
Journal:  Neurology       Date:  2022-04-25       Impact factor: 11.800

3.  Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States.

Authors:  Tyler J Titcomb; Wei Bao; Yang Du; Buyun Liu; Linda G Snetselaar; Terry L Wahls
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-30

Review 4.  Race and ethnicity on MS presentation and disease course.

Authors:  Lilyana Amezcua; Jacob L McCauley
Journal:  Mult Scler       Date:  2020-01-22       Impact factor: 6.312

5.  Racial Differences in Disease Presentation and Management of Intracranial Meningioma.

Authors:  C Lane Anzalone; Amy E Glasgow; Jamie J Van Gompel; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-12-21

Review 6.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

7.  Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis.

Authors:  Vicki Mercado; Deepa Dongarwar; Kristen Fisher; Hamisu M Salihu; George J Hutton; Fernando X Cuascut
Journal:  Biomedicines       Date:  2020-11-25

8.  Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.

Authors:  Arnon Karni; Gil Ben Noon; Tamara Shiner; Ifat Vigiser; Hadar Kolb; Keren Regev
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

9.  Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans.

Authors:  Anne I Boullerne; Mitchell T Wallin; William J Culpepper; Heidi Maloni; Elizabeth A Boots; Dagmar M Sweeney; Douglas L Feinstein
Journal:  Mult Scler Relat Disord       Date:  2021-08-02       Impact factor: 4.808

10.  Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).

Authors:  Annette F Okai; Lilyana Amezcua; Regina R Berkovich; Angel R Chinea; Keith R Edwards; Brian Steingo; Aljoeson Walker; Alan K Jacobs; Nadia Daizadeh; Mitzi J Williams
Journal:  Neurol Ther       Date:  2019-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.